W
e read with interest the article by Chopra et al. (1) suggesting that empirical therapy with cefepime for bloodstream infections due to extended-spectrum-␤-lactamase (ESBL)-producing Enterobacteriaceae is associated with excess mortality. The effectiveness of cefepime would be compromised by ESBL production, resulting in higher MICs (2, 3) .
Several beta-lactamase inhibitors (including clavulanate) are active against ESBLs, and this property forms the basis for in vitro screening of Gram-negative bacteria for these enzymes. Combining clavulanate with oxy-imino-cephalosporins that have relatively low MICs despite ESBL production may provide an alternative to penem use (4) .
We tested the combination of cefepime and amoxicillinclavulanate (AC) in vitro, by comparison with the ceftazidime-AC combination, against 63 previously characterized ESBL-expressing Escherichia coli isolates collected from 2009 to 2011 (5) . In addition, as cefepime is relatively resistant to degradation by AmpC ␤-lactamase, we tested these combinations against 11 E. coli strains with constitutively overexpressed or plasmid-mediated AmpC ␤-lactamase production and ESBLs (Table 1) . We used the disk diffusion method and Clinical and Laboratory Standards Institute (CLSI) guidelines. Isolates were screened for ESBL production by the double-disk synergy test of cefotaxime, ceftazidime, cefepime (30 g), and AC disks on Muller-Hinton agar. AmpC producers were subjected to the double-disk synergy test on cloxacillin-containing MuellerHinton agar (6) . Multiplex PCR was used to characterize ␤-lactamase genes, including bla CTX-M , bla SHV , bla TEM , bla OXA-1 , bla CMY , and bla DHA , using previously described methods and primers, followed by sequencing (7) . The MICs of cefepime, ceftazidime, and AC were determined by the Etest method (AB bioMérieux, Solna, Sweden). The Etest has also been used to evaluate the activity of cefepime or ceftazidime combined with AC. To detect synergy, an AC strip is placed on the agar plate for 1 h and is then replaced by a cefepime or ceftazidime strip, placed on the AC gradient (5, 8) . The MIC of the combination was noted as the value at which the inhibition zone intersected the scale on the Etest strip (Fig. 1) . Synergy was evaluated by calculating the fractional inhibitory concentration (FIC) index (8) .
The distribution of the cefepime, ceftazidime, AC, and combination MIC 50 and MIC 90 values is shown in Table 1 according to the presence of the ESBL, TEM-1, and OXA-1 genes and AmpC production. Among the 74 ESBL-producing E. coli isolates, 85% carried bla CTX-M genes and 14% carried bla TEM-52 or bla SHV-12 ESBL genes. Strains producing CTX-M-15 are known to have higher cefepime MICs than those producing TEM-and SHV-type ESBLs (9) . Coexpression of CTX-M-15 and OXA-1 confers clear resistance to cefepime and ceftazidime.
The cefepime-AC and ceftazidime-AC combinations were synergistic against 73 (FIC index range, 0.021 to 0.0469) and 69 (FIC index range, 0.052 to 0.500) of the 74 strains, respectively. Based on the 2010 CLSI breakpoints of 8 g/ml for cefepime and 4 g/ml for ceftazidime, 16% and 27% of the ESBL-producing strains without AmpC and 27% and 90% of those with AmpC were intermediate or resistant to cefepime and ceftazidime alone, respectively.
The cefepime MIC 90 s were 8 and 48 g/ml for strains without and with AmpC, respectively. However, it has been suggested that a higher-than-standard inoculum may substantially increase cefepime MICs (10). Cefepime-AC was active against all the strains, with MIC 90 s of 0.19 g/ml for strains without AmpC and 0.50 g/ml for strains with AmpC. The MIC 90 s were similar to those of ESBL nonproducers. These low MICs imply that cefepime would be more effective than ceftazidime in infections caused by ESBL-producing E. coli with chromosomal or plasmid-borne AmpC ␤-lactamases (11) .
AC can thus preserve the activity of cefepime in vitro, and synergy between these agents can readily be detected with the Etest, a method suitable for routine use in clinical laboratories before therapeutic application. The pharmacokinetic behavior of clavulanate is compatible with that of cefepime, with a serum half-life of 75 to 90 min and the potential for thrice-daily administration.
The cefepime-AC combination thus deserves clinical evaluation against ESBL-producing E. coli without and with AmpC as an alternative to carbapenem.
